Asset and Financial Position of the Bayer Group

Statement of Cash Flows

Bayer Group Summary Statements of Cash Flows

 

 

Q1 2016

 

Q1 2017

 

Change

 

 

€ million

 

€ million

 

%

2016 figures restated

Net cash provided by (used in) operating activities, continuing operations

 

552

 

826

 

+49.6

Net cash provided by (used in) operating activities, discontinued operations

 

770

 

15

 

−98.1

Net cash provided by (used in) operating activities (total)

 

1,322

 

841

 

−36.4

Net cash provided by (used in) investing activities (total)

 

(462)

 

(1,136)

 

−145.9

Net cash provided by (used in) financing activities (total)

 

823

 

611

 

−25.8

Change in cash and cash equivalents due to business activities

 

1,683

 

316

 

−81.2

Cash and cash equivalents at beginning of period

 

1,859

 

1,899

 

+2.2

Change due to exchange rate movements and to changes in scope of consolidation

 

10

 

9

 

−10.0

Cash and cash equivalents at end of period

 

3,552

 

2,224

 

−37.4

Net cash provided by operating activities

  • Operating cash flow (total) declined by 36.4% in the first quarter of 2017, to €841 million. The prior-year figure included inflows from the divestiture of Diabetes Care. Cash flow from operating activities from continuing operations climbed by a substantial 49.6% to €826 million.

Net cash provided by (used in) investing activities

  • Cash outflows for property, plant and equipment and intangible assets were 14.3% higher in the first quarter of 2017 at €415 million (Q1 2016: €363 million) and included €152 million (Q1 2016: €141 million) at Pharmaceuticals, €24 million (Q1 2016: €39 million) at Consumer Health, €99 million (Q1 2016: €97 million) at Crop Science, €6 million (Q1 2016: €5 million) at Animal Health and €74 million (Q1 2016: €46 million) at Covestro.
  • Cash outflows for acquisitions in the amount of €158 million related to the acquisition of the Cydectin™ product portfolio in the United States in the Animal Health segment.
  • In total, we invested €637 million in mostly current financial assets (Q1 2016: net investment of €144 million in current and noncurrent financial assets).

Net cash provided by (used in) financing activities

  • Net cash inflow for financing activities in the first quarter of 2017 amounted to €611 million, with inflows of €1,460 million from the sale of Covestro shares more than offsetting net loan repayments of €744 million (Q1 2016: net borrowings of €909 million).
  • Net interest expense was €19 million higher at €105 million.